Irinotecan Tillomed

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Tillomed, is a topoisomerase I inhibitor presented as a sterile injectable for intravenous use. It treats metastatic and advanced colorectal cancer in adult patients. GNH USA supplies Irinotecan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Tillomed is a cytotoxic agent used in the management of colorectal cancer and related disease stages. - Metastatic colorectal cancer: provides systemic chemotherapy to reduce tumor burden and extend survival. - Advanced colorectal cancer: delivers targeted DNA damage to inhibit tumor growth in patients with inoperable disease.

Irinotecan therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often delayed and may be severe. - Nausea and vomiting: gastrointestinal upset common after infusion. - Alopecia: temporary hair loss. - Fatigue: generalized tiredness during treatment. - Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe diarrhea leading to dehydration or electrolyte imbalance. - Bowel perforation: rare but life‑threatening gastrointestinal rupture. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Anaphylactic reactions: rare hypersensitivity to the formulation. - Hemorrhagic colitis: inflammation with bleeding in the colon.

Prior to initiating Irinotecan therapy, clinicians should assess patient-specific risk factors and monitor relevant clinical parameters. - Hematologic monitoring: perform baseline and periodic complete blood counts to detect neutropenia. - Liver function: evaluate hepatic enzymes and bilirubin, adjusting dose in impairment. - Renal function: assess creatinine clearance, especially in patients with renal insufficiency. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks; advise against breastfeeding. - Concomitant myelosuppressives: use caution when combined with other bone‑marrow suppressing agents. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with several drug classes, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce SN‑38 exposure. - Concurrent myelosuppressive chemotherapy: heightens risk of severe neutropenia and thrombocytopenia. - Cholinesterase inhibitors (e.g., neostigmine): may exacerbate cholinergic syndrome.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): increase SN‑38 levels, requiring dose adjustment. - Warfarin: potential alteration of INR, necessitating closer coagulation monitoring. - NSAIDs or aspirin: increase risk of gastrointestinal toxicity and bleeding. - UGT1A1 inhibitors (e.g., atazanavir): may raise SN‑38 concentrations, especially in patients with reduced enzyme activity.